Literature DB >> 1568228

p53 and Kirsten-ras mutations in human mesothelioma cell lines.

R A Metcalf1, J A Welsh, W P Bennett, M B Seddon, T A Lehman, K Pelin, K Linnainmaa, L Tammilehto, K Mattson, B I Gerwin.   

Abstract

Twenty cell lines from 17 individuals with malignant mesothelioma have been examined for p53 alterations by direct sequencing of genomic DNA, by evaluation of mRNA expression levels, and by immunocytochemical analysis of p53 protein expression in comparison with normal human pleural mesothelial cells. The results of this study show p53 abnormalities in cell lines from 3 individuals. These include 2 point mutations and one null cell line. Interestingly, while both cell lines with point mutations exhibit high levels of p53 protein, normal mesothelial cells as well as 12 of the mesotheliomas evaluated express low but significant levels. In addition, sequencing of K-ras at codons 12, 13, and 61 reveals wild-type sequence in all 20 mesothelioma cell lines. The capacity to induce tumors in athymic nude mice did not correlate with the presence of a p53 mutation or elevated p53 protein levels. These data suggest that neither p53 alteration nor K-ras activation constitutes a critical step in the development of human mesothelioma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568228

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  Lung cancer cell lines as tools for biomedical discovery and research.

Authors:  Adi F Gazdar; Luc Girard; William W Lockwood; Wan L Lam; John D Minna
Journal:  J Natl Cancer Inst       Date:  2010-08-02       Impact factor: 13.506

2.  Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.

Authors:  Gavin J Gordon; Graham N Rockwell; Roderick V Jensen; James G Rheinwald; Jonathan N Glickman; Joshua P Aronson; Brian J Pottorf; Matthew D Nitz; William G Richards; David J Sugarbaker; Raphael Bueno
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

Review 3.  Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.

Authors:  J W Upham; M J Garlepp; A W Musk; B W Robinson
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

4.  Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma.

Authors:  K Segers; H Backhovens; S K Singh; J De Voecht; M Ramael; C Van Broeckhoven; E Van Marck
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  Mechanisms of asbestos carcinogenesis and toxicity: the amphibole hypothesis revisited.

Authors:  B T Mossman
Journal:  Br J Ind Med       Date:  1993-08

6.  DNA copy number gains in malignant pleural mesothelioma.

Authors:  Masashi Furukawa; Shinichi Toyooka; Tatsuro Hayashi; Hiromasa Yamamoto; Nobukazu Fujimoto; Junichi Soh; Shinsuke Hashida; Kazuhiko Shien; Hiroaki Asano; Keisuke Aoe; Kazunori Okabe; Harvey I Pass; Kazunori Tsukuda; Takumi Kishimoto; Shinichiro Miyoshi
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

7.  Establishment and mutation analysis of a novel malignant peritoneal mesothelioma cell line, TU-MM-1, using whole genome sequencing.

Authors:  Nao Oumi; Hiroaki Itamochi; Hiroaki Komatsu; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Jun Chikumi; Seiya Sato; Michiko Nonaka; Akiko Kudoh; Tasuku Harada
Journal:  Hum Cell       Date:  2015-06-13       Impact factor: 4.174

Review 8.  The genetic susceptibility in the development of malignant pleural mesothelioma.

Authors:  Ombretta Melaiu; Federica Gemignani; Stefano Landi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

9.  Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma.

Authors:  Ryota Hama; Yoshiyuki Watanabe; Kanako Shinada; Yosuke Yamada; Yuka Ogata; Yoshihito Yoshida; Tomohiro Tamura; Tetsuya Hiraishi; Ritsuko Oikawa; Jo Sakurai; Tadateru Maehata; Hirotaka Koizumi; Fumio Itoh
Journal:  Tumour Biol       Date:  2012-07-27

10.  Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies.

Authors:  Feng An; Daryl C Drummond; Shannon Wilson; Dmitri B Kirpotin; Stephen L Nishimura; V Courtney Broaddus; Bin Liu
Journal:  Mol Cancer Ther       Date:  2008-03-04       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.